Compare Ascendis Pharma A/S (ASND) vs Western Union Co (WU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Western Union Co — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Western Union Co trades at $7.85 (market cap $2.45B). The key difference: Ascendis Pharma A/S is far larger — about 7.2× Western Union Co's market cap, and Western Union Co pays a 11.99% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WU | |
|---|---|---|
Market Cap | $17.74B | $2.45B |
Sector | Health | Technology |
52-Week High | $277.18 | $10.28 |
52-Week Low | $163.32 | $7.04 |
Enterprise Value | $18.11B | $2.14B |
Dividend Yield | — | 11.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Western Union (WU) trades at $7.84, up 0.26% on the day, with a bearish technical signal despite recent positive earnings beats. The stock shows strong profitability with a 10.88% net margin and attractive valuation ratios, including a P/E of 5.76. Recent news highlights strategic partnerships, such as the integration with Total Wireless, expanding its digital payment reach.
The outlook is mixed; low valuations and dividend yield present opportunity, but declining revenue, a recent earnings miss, and high debt pose risks. Analyst sentiment is cautious with only 12.5% buy ratings. Investors should weigh the value proposition against execution challenges in a competitive money transfer landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
